Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
Healthcare
$1.61 -0.87%
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
52W Low $2.01High $48.91
Volume 0.02M
Average 0.34M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$7.82M
FY 2025 · Annual
Net Income
-$8.98M
FY 2025 · Annual
Income Statement
USD
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| 189.37M | 189.37M | 47.34M | |
| 189.37M | 189.37M | 47.34M |
PLYX Earnings Waterfall · TTM
NASDAQ:PLYX · Revenue to Net Income
Key Ratios
EPS$-0.10
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-778.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$6.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.10, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Sep 14, 2026 | |
| 8-K | Current report | Sep 1, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 | |
| ARS | ARS filing | Jul 28, 2026 |
How much revenue does PLYX generate?
Polaryx Therapeutics, Inc. Common Stock (PLYX) reported $0.00 of revenue in fiscal 2025.
Is PLYX profitable?
Polaryx Therapeutics, Inc. Common Stock (PLYX) reported -$8.98M of net income.
Continue the stock analysis
Jump to another research area for this company.